<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   The management of the surgical patient taking glucocorticoids
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       The management of the surgical patient taking glucocorticoids
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        The management of the surgical patient taking glucocorticoids
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amir H Hamrahian, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanziana Roman, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stacey Milan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sally E Carty, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic glucocorticoid therapy can suppress the hypothalamic-pituitary-adrenal (HPA) axis and, during times of stress such as surgery, the adrenal glands may not respond appropriately. Protocols for "stress dose" steroids followed reports in the 1950s of possible surgery-associated adrenal insufficiency due to sudden preoperative withdrawal of glucocorticoids. However, some studies have questioned the need for supplemental perioperative glucocorticoids beyond the maintenance dose.
        </p>
        <p>
         The management of the surgical patient on chronic glucocorticoid therapy is reviewed here. Perioperative glucocorticoid regimens for patients taking replacement glucocorticoid for primary adrenal insufficiency are addressed separately. (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H177132320">
         <span class="h1">
          PERIOPERATIVE GLUCOCORTICOIDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of stress doses of glucocorticoids, such as 300 mg/day of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         for several days [
         <a href="#rid1">
          1-3
         </a>
         ], had become a common perioperative practice for patients on glucocorticoid therapy, based upon early case reports of intraoperative adrenal crisis after abrupt withdrawal of glucocorticoids [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         However, a number of studies suggest that supplemental exogenous stress glucocorticoids may not be needed to meet the demands of perioperative stress [
         <a href="#rid1">
          1,6-14
         </a>
         ]. However, all studies are limited by small numbers of patients [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Two reports suggest that stress doses may not be needed even in patients on glucocorticoids undergoing major colorectal surgery. In a 2012 retrospective cohort study of patients with inflammatory bowel disease undergoing such surgery, administration of low-dose perioperative steroids (the equivalent of their preoperative dose given intravenously), no patients required vasopressors for hemodynamic instability or additional steroids for adrenal insufficiency [
         <a href="#rid15">
          15
         </a>
         ]. In a randomized trial of similar patients undergoing major colorectal surgery, no differences in postural hypotension or adrenal insufficiency were seen between those receiving high-dose glucocorticoids (
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         100 mg intravenously three times daily) or low-dose glucocorticoids (the equivalent of their preoperative dose given intravenously) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Although these data are reassuring, our approach to glucocorticoid dosing is based upon the likelihood of hypothalamic-pituitary axis (HPA) suppression and the magnitude of the surgical stress.
        </p>
        <p class="headingAnchor" id="H4021564451">
         <span class="h2">
          Potential adverse effects of perioperative glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to suppression of the HPA axis, perioperative glucocorticoid therapy may cause a number of other problems:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired wound healing [
         <a href="#rid17">
          17
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased friability of skin, superficial blood vessels, and other tissues (eg, mild pressure may cause hematoma or skin ulceration, removing adhesive tape may tear the skin, and sutures may tear the gut wall)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased risk of fracture, infections, gastrointestinal hemorrhage, or ulcer [
         <a href="#rid18">
          18,19
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         One important reason to avoid supraphysiologic administration of glucocorticoids perioperatively, unless absolutely necessary, is that they have acute side effects that can influence surgical outcomes [
         <a href="#rid7">
          7,20
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperglycemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid retention
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased risk of infection (see
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2342035300">
         <span class="h2">
          Individualized approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The current approach is to determine perioperative glucocorticoid coverage based upon the patient's history of glucocorticoid intake, as well as the type and duration of surgery planned [
         <a href="#rid2">
          2,21-23
         </a>
         ].
        </p>
        <p>
         An anesthetic agent,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         , should be avoided in patients at risk for adrenal suppression and adrenal crisis. This is a commonly used anesthetic induction agent known to have properties of inhibiting steroid synthesis and precipitating acute adrenal insufficiency [
         <a href="#rid24">
          24
         </a>
         ]. While etomidate has many benefits in specific clinical settings, it is best avoided in patients with possible HPA suppression. If it is used, patients need to receive glucocorticoid coverage perioperatively or be closely monitored for any clinical features suggestive of adrenal insufficiency [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         In patients with possible HPA suppression, the presence of unexplained nausea, vomiting, hypotension, orthostasis, change in mental status, hyponatremia, or hyperkalemia should prompt checking a random cortisol and, depending on the urgency of the situation, may require empiric therapy with additional corticosteroids. Additionally, postoperative stressors, such as infection, myocardial infarction, bleeding, or other complications may also prompt the administration of additional glucocorticoids.
        </p>
        <p>
         Patients who are taking glucocorticoids should be monitored carefully for infection postoperatively because glucocorticoids may suppress the fever response.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CORTISOL SECRETION DURING STRESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute physical or psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, resulting in increased plasma corticotropin (ACTH) and serum cortisol concentrations. Stress exerts its effects by stimulating the hypothalamus to release ACTH secretagogues, with corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) being the most important [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         Surgery is one of the most potent activators of the HPA axis. The degree of activation of the HPA axis depends on both the type of surgery performed and the anesthetic agents used during the procedure [
         <a href="#rid28">
          28,29
         </a>
         ]. Plasma ACTH concentrations increase at the time of incision and during surgery, but the greatest ACTH and cortisol secretion occurs during reversal of anesthesia, extubation, and, in the immediate postoperative recovery period, primarily in response to pain [
         <a href="#rid30">
          30,31
         </a>
         ]. The response is mediated by afferent nerve impulses since it can be abolished by interrupting the neural connections from the operative site, such as by sectioning the spinal cord [
         <a href="#rid32">
          32
         </a>
         ], epidural anesthesia [
         <a href="#rid33">
          33
         </a>
         ], or local anesthesia. The plasma ACTH and serum cortisol responses to surgery can also be reduced by opiate drugs [
         <a href="#rid31">
          31,34
         </a>
         ].
        </p>
        <p>
         There is considerable variation in the increase in cortisol secretion among individuals undergoing surgery; this variability is in part due to concomitant medication use, age, and concurrent illness.
        </p>
        <p>
         However, in general, cortisol secretion is proportional to the degree of surgical stress:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The normal basal secretion of cortisol from the adrenal gland is approximately 8 to 10 mg/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During a minor surgery or illness, secretion of cortisol increases to approximately 50 mg/day [
         <a href="#rid21">
          21
         </a>
         ]. Small, transient cortisol responses are seen with minor stress (eg, inguinal hernia repair), returning to baseline within 24 hours after uncomplicated surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients exposed to greater surgical stress (eg, subtotal colectomy) have greater cortisol responses (75 to 100 mg/day), normalizing by postoperative day 5 [
         <a href="#rid28">
          28,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cortisol secretion rate can reach 200 to 500 mg/day with severe stress (such as major trauma), but secretion rates greater than 200 mg/day in the 24 hours after surgery are rare [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          APPROACH BASED UPON HPA AXIS SUPPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exogenous glucocorticoids exert negative feedback control on the hypothalamic-pituitary-adrenal (HPA) axis by suppressing corticotropin-releasing hormone (CRH) secretion and, consequently, corticotropin (ACTH) secretion. This leads to adrenal atrophy and loss of cortisol secretory capability [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         The time course for recovery of the HPA axis after stopping glucocorticoid therapy following a prolonged treatment course is variable and depends upon a variety of factors including the dose, time of day, and duration of glucocorticoid therapy [
         <a href="#rid37">
          37-39
         </a>
         ]. Drugs such as azole antifungal agents and
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         that inhibit cytochrome P450 3A4 enzyme pathway may result in increased serum level of glucocorticoids. Such combination may result in more pronounced suppression of HPA axis. A detailed drug history and the presence of Cushingoid features may help identify such patients. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Adverse effect of medications'
         </a>
         .)
        </p>
        <p>
         In patients whose glucocorticoid history is uncertain, biochemical evaluation of HPA may be considered prior to surgery or a short course of glucocorticoid therapy can be given perioperatively. (See
         <a class="local">
          'Evaluation of HPA axis suppression'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3179742">
         <span class="h2">
          Nonsuppressed HPA axis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         doses of less than 5 mg/day given in the morning do not suppress the hypothalamic-pituitary-adrenal (HPA) axis. The equivalent morning doses of other glucocorticoids (eg, 4 mg/day of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , 0.5 mg/day of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , or 20 mg/day of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         ) will have a similar effect (
         <a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/124.html" rel="external">
          "Pharmacologic use of glucocorticoids"
         </a>
         .)
        </p>
        <p>
         We suggest that the following groups of patients do not need additional perioperative glucocorticoid coverage, because they are
         <strong>
          not
         </strong>
         considered to have suppression of their HPA axis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any patient who has been taking any dose of glucocorticoid for less than three weeks [
         <a href="#rid40">
          40
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have received
         <strong>
          morning
         </strong>
         doses of
         <strong>
          less
         </strong>
         than 5 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or its equivalent for any length of time [
         <a href="#rid41">
          41,42
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients being treated with
         <strong>
          less
         </strong>
         than 10 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or its equivalent every other day [
         <a href="#rid43">
          43-45
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         These patients can be safely maintained on their normal daily dose of glucocorticoids in the perioperative period. Furthermore, these patients do not require testing for HPA axis suppression, as the testing does not accurately predict development of adrenal crisis postoperatively [
         <a href="#rid46">
          46-48
         </a>
         ]. Monitoring of these patients for any evidence of hemodynamic instability perioperatively should be sufficient [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3179792">
         <span class="h2">
          Suppressed HPA axis patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast, patients who should be assumed to have functional suppression of hypothalamic-pituitary-adrenal (HPA) function include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any patient who is currently taking more than 20 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or its equivalent (eg, 16 mg/day of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , 2 mg/day of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , or 80 mg/day of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         ) for more than three weeks [
         <a href="#rid49">
          49
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any patient on glucocorticoids who has clinical Cushing's syndrome
        </p>
        <p>
        </p>
        <p>
         We suggest that these patients be treated with supplemental glucocorticoids in the perioperative period in accordance with the magnitude of the stress (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3179806">
         <span class="h2">
          Intermediate patients (HPA suppression unknown)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients currently taking doses of 5 to 20 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or its equivalent) for more than three weeks have considerable variability in hypothalamic-pituitary-adrenal (HPA) axis suppression that does not correlate well with age, sex, dose, or duration of therapy. This variability is probably due to differences in rates of glucocorticoid metabolism (
         <a class="graphic graphic_figure graphicRef59504" href="/z/d/graphic/59504.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Additionally, doses lower than the equivalent of 5 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         daily taken in the evening may disrupt the normal diurnal variation and the way the patient responds to surgical stress [
         <a href="#rid41">
          41,50
         </a>
         ].
        </p>
        <p>
         We suggest that all patients in this intermediate category undergo preoperative evaluation of their HPA axis. (See
         <a class="local">
          'Evaluation of HPA axis suppression'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H73207804">
         <span class="h3">
          Glucocorticoid use in past year
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient who has discontinued glucocorticoids in the year prior to surgery presents another problem. Early studies found that profound suppression of the HPA axis could take up to one year to recover fully [
         <a href="#rid37">
          37,38
         </a>
         ]. This led some to recommend the administration of glucocorticoids to any patient who had been on
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         doses of more than 5 mg/day for more than three weeks in the 6 to 12 months prior to surgery, but available evidence does not support this approach [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         For patients who are currently off glucocorticoids but used them in the past year, we suggest the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who received regimens that would not be expected to suppress the HPA axis do not require testing. (See
         <a class="local">
          'Nonsuppressed HPA axis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All other patients who received regimens of either longer duration or higher doses of glucocorticoids that could have potentially suppressed the HPA axis (eg, the suppressed or intermediate "unknown" HPA suppression categories) should undergo preoperative assessment of their HPA axis beginning with a morning serum cortisol. (See
         <a class="local">
          'Evaluation of HPA axis suppression'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Inhaled and topical glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic use of inhaled or high-potency, topical glucocorticoids has potential to cause HPA axis suppression, although this rarely manifests as overt adrenal insufficiency [
         <a href="#rid52">
          52
         </a>
         ]. The degree of HPA axis suppression is dependent on potency, dose, duration, frequency, and timing of glucocorticoid administration.
        </p>
        <p>
         The effect of inhaled and topical glucocorticoids on the HPA axis is illustrated by the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The result of studies of inhaled glucocorticoids (IGCs) on HPA axis function in asthmatic adults are inconsistent because they have often been uncontrolled, and study subjects have received intermittent courses of oral glucocorticoids, which may also affect the HPA axis [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children are at higher risk of HPA suppression from IGCs. Two retrospective studies identified a number of cases of acute adrenal crisis in patients using IGCs (at doses ranging from 500 to 2000 mcg daily) [
         <a href="#rid52">
          52,55
         </a>
         ]. This occurred disproportionately in children and with the use of
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of 21 studies of urinary cortisol excretion and 13 studies of morning serum cortisol concentrations in patients taking IGCs found evidence of HPA axis suppression that was most common with IGC doses greater than 800 mcg daily but was often absent even at higher doses [
         <a href="#rid53">
          53
         </a>
         ]. HPA axis suppression was seen with lower daily doses of
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         (750 mcg daily) than with
         <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">
          beclomethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         (1500 mcg daily). (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids", section on 'Adrenal suppression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The inhaled agent,
         <a class="drug drug_general" data-topicid="8537" href="/z/d/drug information/8537.html" rel="external">
          ciclesonide
         </a>
         , may theoretically be less likely to cause biochemical evidence of adrenal suppression due to differences in pharmacokinetics. A meta-analysis of four studies using doses of 160 to 640 mcg/day did not show evidence for suppression of morning or 24-hour urinary cortisol [
         <a href="#rid56">
          56
         </a>
         ], but further data are needed to confirm that HPA suppression does not occur with this agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Topical corticosteroids, particularly class I agents (the strongest, eg, super potent), can cause significant HPA axis suppression using as little as 2 grams/day for two or more weeks [
         <a href="#rid57">
          57-59
         </a>
         ]. In one report, temporary reversible suppression was noted in 8 of 40 patients (20 percent) with psoriasis treated with super potent, topical corticosteroids for three weeks [
         <a href="#rid60">
          60
         </a>
         ]. In contrast, topical
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate at a mean dose of 23 grams per week for six weeks did not result in significant alteration of the HPA axis in patients being treated for vitiligo [
         <a href="#rid61">
          61
         </a>
         ]. Factors that predispose to HPA suppression include use of high potency corticosteroids, chronic use, application to highly permeable areas such as face or genitalia, treatment of large areas, occlusion, poor skin integrity, liver failure, and young age. Routine use of even mild corticosteroids in young children can cause HPA axis suppression. Systemic absorption is increased when there is an altered skin barrier, which is common in the conditions for which these medications are prescribed. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Systemic'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         We recommend evaluation of adrenal function perioperatively in patients who have been on:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥750 mcg daily of
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         (1500 mcg daily for other IGCs) for more than three weeks prior to surgery
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥2 g/day of high potency or super high potency topical corticosteroids (class I-III) for more than three weeks prior to surgery
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, patients who appear Cushingoid or exhibit signs or symptoms of adrenal insufficiency should have their HPA axis evaluated [
         <a href="#rid62">
          62
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3965855">
         <span class="h3">
          Intraarticular and spinal glucocorticoid injections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic absorption occurs after intraarticular glucocorticoid [
         <a href="#rid63">
          63-66
         </a>
         ], and HPA axis suppression has been described after both intraarticular and spinal injections [
         <a href="#rid67">
          67-69
         </a>
         ]. Several factors, including the dose, interval, and the number of glucocorticoid injections, have an impact on the severity of HPA axis suppression [
         <a href="#rid63">
          63,70
         </a>
         ].
        </p>
        <p>
         Although the risk of perioperative adrenal crisis is likely to be low in patients with a history of previous glucocorticoid injections, we suggest HPA axis evaluation in those who have received three or more intraarticular or spinal glucocorticoid injections within three months prior to surgery [
         <a href="#rid68">
          68
         </a>
         ] or those who appear Cushingoid on exam [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          EVALUATION OF HPA AXIS SUPPRESSION
         </span>
        </p>
        <p class="headingAnchor" id="H63695818">
         <span class="h2">
          Intermediate patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that all patients in the intermediate category of hypothalamic-pituitary-adrenal (HPA) axis suppression (eg, status of HPA axis suppression is unknown) undergo preoperative evaluation of their HPA axis.
        </p>
        <p class="headingAnchor" id="H884513">
         <span class="h3">
          Morning serum cortisol
         </span>
         <span class="headingEndMark">
          —
         </span>
         The measurement of morning (prior to 8 AM) serum cortisol has been described as a good screening method for evaluation of secondary adrenal insufficiency, with a good correlation with maximum cortisol achieved during insulin-induced hypoglycemia [
         <a href="#rid71">
          71,72
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients on chronic glucocorticoid therapy, an early morning cortisol &lt;5 mcg/dL (138 nmol/L) 24-hour off glucocorticoid replacement dose is highly suggestive of an impaired HPA axis with the need for additional glucocorticoid intake perioperatively (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid73">
          73,74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with an early morning cortisol level &gt;10 mcg/dL (275 nmol/L) likely do
         <strong>
          not
         </strong>
         have a significant impairment of the HPA axis and may be continued on their current glucocorticoid replacement dose on the day of surgery [
         <a href="#rid71">
          71,72
         </a>
         ]. Such patients do not need additional perioperative glucocorticoid therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with an early morning cortisol level between 5 to 10 mcg/dL (138 to 275 nmol/L), we suggest further evaluation with a corticotropin (ACTH) stimulation test or empiric additional perioperative glucocorticoid therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H884520">
         <span class="h3">
          ACTH stimulation tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest measurement of serum cortisol at 30 minutes after 250 mcg corticotropin (ACTH) stimulation for preoperative evaluation of the HPA axis. A cortisol level &gt;18 mcg/dL (497 nmol/L) 30 minutes after 250 mcg ACTH stimulation predicts an adequate adrenal reserve during surgery with no need for glucocorticoid coverage perioperatively [
         <a href="#rid48">
          48,75,76
         </a>
         ].
        </p>
        <p>
         Patients with an inadequate response should receive additional glucocorticoid coverage (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         The
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         may be normal in patients with acute (within two to four weeks) ACTH deficiency (as might occur soon after pituitary surgery) and, therefore, cannot be relied upon as an indicator of a normal HPA axis in such circumstances [
         <a href="#rid77">
          77
         </a>
         ]. An insulin tolerance test or
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         stimulation test may be done to evaluate HPA axis in such patients. However, these tests are not practical in most clinical settings, and therefore, we suggest empiric replacement with glucocorticoids in patients with suspected acute ACTH deficiency due to recent pituitary surgery. (See
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
         A normal cortisol response during the
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         confirms adequate cortisol reserve during surgery and a lack of need for glucocorticoid coverage perioperatively. However, a normal clinical response to surgical stress has been reported in three studies of patients with an inadequate response to high-dose ACTH stimulation test while being maintained on their usual daily glucocorticoid dose [
         <a href="#rid1">
          1,8,48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H63695768">
         <span class="h2">
          Urgent or emergency surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who require urgent or emergency surgery who fall into the intermediate category described above (eg, they have taken glucocorticoids but the degree of suppression of their HPA axis is unknown) should receive empiric perioperative glucocorticoid coverage. Our recommendations for specific glucocorticoid regimens are based upon the type and anticipated duration of surgery (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ). Delaying surgery to perform evaluation of the HPA axis would be inappropriate in this setting.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of stress doses of glucocorticoids has become a common perioperative practice for patients on glucocorticoid therapy. However, available data suggest that these doses are excessive and unnecessary in most patients.
        </p>
        <p>
         The current approach is to determine glucocorticoid coverage based upon the patient's history of glucocorticoid intake and likelihood of hypothalamic-pituitary-adrenal (HPA) axis suppression, as well as the type and duration of surgery.
        </p>
        <p>
         We suggest the following approach for perioperative glucocorticoid coverage:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsuppressed HPA axis – For patients who have been taking exogenous glucocorticoids of any dose for less than three weeks, morning
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (&lt;5 mg daily or its equivalent) for any duration, or less than 10 mg of prednisone or its equivalent every other day, we suggest continuing the same glucocorticoid regimen perioperatively (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). These patients are unlikely to have a suppressed HPA axis, and neither preoperative evaluation of the HPA axis nor supraphysiologic doses of glucocorticoids are needed. (See
         <a class="local">
          'Nonsuppressed HPA axis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suppressed HPA axis – For patients who are currently taking
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         &gt;20 mg/day for three weeks or more and in patients with a Cushingoid appearance, we suggest additional perioperative glucocorticoid coverage, because HPA axis suppression should be assumed to be present (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Our recommendations for specific glucocorticoid regimens are based upon the type and anticipated duration of surgery (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate HPA suppression – For all other patients, the degree of HPA axis suppression is unknown, and biochemical evaluation of the HPA axis should be performed. (See
         <a class="local">
          'Intermediate patients (HPA suppression unknown)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although the risk of perioperative adrenal crisis is likely to be low in patients with a history of previous glucocorticoid injections, we also suggest HPA axis evaluation in those who have received three or more intraarticular or spinal glucocorticoid injections within three months prior to surgery. (See
         <a class="local">
          'Intraarticular and spinal glucocorticoid injections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The approach to patients taking inhaled or topical glucocorticoids is described above. (See
         <a class="local">
          'Inhaled and topical glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first step in the evaluation of the HPA axis is a morning (8 AM) serum cortisol (24-hour off glucocorticoid replacement dose).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the 8 AM cortisol is &lt;5 mcg/dL (138 nmol/L), the patient is likely to have a suppressed HPA axis, and we therefore suggest additional glucocorticoid intake perioperatively (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the 8 AM cortisol is &gt;10 mcg/dL (275 nmol/L), the patient likely does
         <strong>
          not
         </strong>
         have a significant impairment of the HPA axis, and the patient may be continued on his current glucocorticoid replacement dose on the day of surgery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If 8 AM cortisol level is between 5 to 10 mcg/dL (138 to 275 nmol/L), we suggest further evaluation with a corticotropin (ACTH) stimulation test (if time permits) or empiric additional glucocorticoid therapy (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who undergo a standard 250 mcg
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         , if serum cortisol is &lt;18 mcg/dL (497 nmol/L) at 30 minutes in response to ACTH, we suggest perioperative glucocorticoid coverage (
         <a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">
          table 2
         </a>
         ). For those with a serum cortisol response &gt;18 mcg/dL (497 nmol/L), no coverage is needed (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who require urgent or emergency surgery who fall into the intermediate category described above (eg, they have taken glucocorticoids but the degree of HPA axis suppression is unknown), we suggest empiric perioperative glucocorticoid coverage (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The issue of supplemental glucocorticoids for patients with known adrenal insufficiency already taking glucocorticoids is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2425296470">
         <span class="h1">
          DISCLOSURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
        <p class="headingAnchor" id="H3564762">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate would like to acknowledge Gail Welsh, MD, Ellen Manzullo, MD, and Lynnette Nieman, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bromberg JS, Alfrey EJ, Barker CF, et al. Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation 1991; 51:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salem M, Tainsh RE Jr, Bromberg J, et al. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 1994; 219:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw M, Mandell BF. Perioperative management of selected problems in patients with rheumatic diseases. Rheum Dis Clin North Am 1999; 25:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FRASER CG, PREUSS FS, BIGFORD WD. Adrenal atrophy and irreversible shock associated with cortisone therapy. J Am Med Assoc 1952; 149:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LEWIS L, ROBINSON RF, YEE J, et al. Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment. Ann Intern Med 1953; 39:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rossum EF, Feelders RA. [When is a perioperative glucocorticoid stress-dose regime indicated?]. Ned Tijdschr Geneeskd 2015; 159:A8277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathis AS, Shah NK, Mulgaonkar S. Stress dose steroids in renal transplant patients undergoing lymphocele surgery. Transplant Proc 2004; 36:3042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery 1997; 121:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bromberg JS, Baliga P, Cofer JB, et al. Stress steroids are not required for patients receiving a renal allograft and undergoing operation. J Am Coll Surg 1995; 180:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman RJ, Schiff CF, Bromberg JS. Use of supplemental steroids in patients having orthopaedic operations. J Bone Joint Surg Am 1995; 77:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomason JM, Girdler NM, Kendall-Taylor P, et al. An investigation into the need for supplementary steroids in organ transplant patients undergoing gingival surgery. A double-blind, split-mouth, cross-over study. J Clin Periodontol 1999; 26:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yong SL, Coulthard P, Wrzosek A. Supplemental perioperative steroids for surgical patients with adrenal insufficiency. Cochrane Database Syst Rev 2012; 12:CD005367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Cardenas SM, Santhanam P, Morris-Wiseman L, et al. Perioperative Evaluation and Management of Patients on Glucocorticoids. J Endocr Soc 2022; 7:bvac185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaghiyan K, Melmed G, Murrell Z, Fleshner P. Safety and feasibility of using low-dose perioperative intravenous steroids in inflammatory bowel disease patients undergoing major colorectal surgery: A pilot study. Surgery 2012; 152:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaghiyan K, Melmed GY, Berel D, et al. A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery. Ann Surg 2014; 259:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BOLLET AJ, BLACK R, BUNIM JJ. Major undesirable side-effects resulting from prednisolone and prednisone. J Am Med Assoc 1955; 158:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff RL, Welsh GA. Perioperative evaluation and management of the patient with endocrine dysfunction. Med Clin North Am 2003; 87:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997; 337:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lange DW, Kars M. Perioperative glucocorticosteroid supplementation is not supported by evidence. Eur J Intern Med 2008; 19:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner RL, White PF, Kan PB, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984; 310:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray H, Marik PE. Etomidate for endotracheal intubation in sepsis: acknowledging the good while accepting the bad. Chest 2005; 127:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoni FA. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev 1986; 7:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 1994; 15:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chernow B, Alexander HR, Smallridge RC, et al. Hormonal responses to graded surgical stress. Arch Intern Med 1987; 147:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour SA. Steroids and the surgical patient. Med Clin North Am 2001; 85:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udelsman R, Norton JA, Jelenich SE, et al. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab 1987; 64:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Norton AJ, Flemma RJ, Findling JW. Inhibition of the adrenocorticotropin response to surgery in humans: interaction between dexamethasone and fentanyl. J Clin Endocrinol Metab 1987; 65:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           REDGATE ES. Spinal cord and ACTH release in adrenalectomized rats following electrical stimulation. Endocrinology 1962; 70:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandt M, Kehlet H, Binder C, et al. Effect of epidural analgesia on the glycoregulatory endocrine response to surgery. Clin Endocrinol (Oxf) 1976; 5:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JM, Reier CE, Lanese RR, Rower M. Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans. J Clin Endocrinol Metab 1974; 38:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yong SL, Marik P, Esposito M, Coulthard P. Supplemental perioperative steroids for surgical patients with adrenal insufficiency. Cochrane Database Syst Rev 2009; :CD005367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976; 55:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy. Lancet 1967; 2:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GRABER AL, NEY RL, NICHOLSON WE, et al. NATURAL HISTORY OF PITUITARY-ADRENAL RECOVERY FOLLOWING LONG-TERM SUPPRESSION WITH CORTICOSTEROIDS. J Clin Endocrinol Metab 1965; 25:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westerhof L, Van Ditmars MJ, Der Kinderen PJ, et al. Recovery of adrenocortical function during long-term treatment with corticosteroids. Br Med J 1972; 2:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Axelrod L. Perioperative management of patients treated with glucocorticoids. Endocrinol Metab Clin North Am 2003; 32:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993; 95:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HARTER JG, REDDY WJ, THORN GW. STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN. N Engl J Med 1963; 269:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauci AS. Alternate-day corticosteroid therapy. Am J Med 1978; 64:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman GL, Nolsn CM. Adrenocortical responsiveness after alternate-day corticosteroid therapy. N Engl J Med 1968; 278:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg 2008; 143:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kehlet H, Binder C. Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients. Br J Anaesth 1973; 45:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kehlet H, Binder C. Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients. Br Med J 1973; 2:147.
          </a>
         </li>
         <li class="breakAll">
          Christy NP. Corticosteroid withdrawal. In: Current Therapy in Endocrinology and Metabolism, 3rd Ed, Bardin CW (Ed), BC Decker, New York 1988. p.113.
         </li>
         <li>
          <a class="nounderline abstract_t">
           NICHOLS T, NUGENT CA, TYLER FH. DIURNAL VARIATION IN SUPPRESSION OF ADRENAL FUNCTION BY GLUCOCORTICOIDS. J Clin Endocrinol Metab 1965; 25:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaghiyan K, Melmed G, Murrell Z, Fleshner P. Are high-dose perioperative steroids necessary in patients undergoing colorectal surgery treated with steroid therapy within the past 12 months? Am Surg 2011; 77:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White M, Crisalida T, Li H, et al. Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma. Ann Allergy Asthma Immunol 2006; 96:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zöllner EW, Lombard C, Galal U, et al. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids--more common than expected? J Pediatr Endocrinol Metab 2011; 24:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function. J Am Acad Dermatol 1987; 16:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Fuente-García A, Gómez-Flores M, Mancillas-Adame L, et al. Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study. Indian Dermatol Online J 2014; 5:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tempark T, Phatarakijnirund V, Chatproedprai S, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine 2010; 38:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeback JS, Chakraborty J, English J, et al. Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis. Ann Rheum Dis 1980; 39:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           OKA M. Absorption of acetates of hydrocortisone, delta 1-hydrocortisone and cortisone from the joint cavity into the circulation. J Clin Endocrinol Metab 1958; 18:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           YOUNG HH, WARD LE, HENDERSON ED. The use of hydrocortisone acetate (compound F acetate) in the treatment of some common orthopaedic conditions. J Bone Joint Surg Am 1954; 36-A:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lansang MC, Farmer T, Kennedy L. Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr Pract 2009; 15:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duclos M, Guinot M, Colsy M, et al. High risk of adrenal insufficiency after a single articular steroid injection in athletes. Med Sci Sports Exerc 2007; 39:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay J, Findling JW, Raff H. Epidural triamcinolone suppresses the pituitary-adrenal axis in human subjects. Anesth Analg 1994; 79:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib G, Khazin F, Jabbour A, et al. Simultaneous bilateral knee injection of methylprednisolone acetate and the hypothalamic-pituitary adrenal axis: a single-blind case-control study. J Investig Med 2014; 62:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong RD, English J, Gibson T, et al. Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate. Ann Rheum Dis 1981; 40:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hägg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf) 1987; 26:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab 2003; 88:4193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test. Horm Metab Res 2009; 41:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Endert E, Ouwehand A, Fliers E, et al. Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency. Neth J Med 2005; 63:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dekkers OM, Timmermans JM, Smit JW, et al. Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency. Eur J Endocrinol 2011; 164:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickstein G, Saiegh L. Low-dose and high-dose adrenocorticotropin testing: indications and shortcomings. Curr Opin Endocrinol Diabetes Obes 2008; 15:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borst GC, Michenfelder HJ, O'Brian JT. Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease. N Engl J Med 1982; 306:1462.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 146 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1847249" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Adrenal suppression and steroid supplementation in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8161268" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10467631" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Perioperative management of selected problems in patients with rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14945970" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Adrenal atrophy and irreversible shock associated with cortisone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13065993" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25650031" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : [When is a perioperative glucocorticoid stress-dose regime indicated?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15686690" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Stress dose steroids in renal transplant patients undergoing lymphocele surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9037222" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2336689" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7749527" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Stress steroids are not required for patients receiving a renal allograft and undergoing operation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8550646" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Use of supplemental steroids in patients having orthopaedic operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10487307" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : An investigation into the need for supplementary steroids in organ transplant patients undergoing gingival surgery. A double-blind, split-mouth, cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23235622" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Supplemental perioperative steroids for surgical patients with adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36545644" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Perioperative Evaluation and Management of Patients on Glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22503320" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Safety and feasibility of using low-dose perioperative intravenous steroids in inflammatory bowel disease patients undergoing major colorectal surgery: A pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23774314" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10326344" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Steroids, retinoids, and wound healing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2690289" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Risk of infectious complications in patients taking glucocorticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14381192" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Major undesirable side-effects resulting from prednisolone and prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12575889" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Perioperative evaluation and management of the patient with endocrine dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9345079" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Corticosteroid therapy in severe illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11779267" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Corticosteroid supplementation for adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18848181" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Perioperative glucocorticosteroid supplementation is not supported by evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6325910" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Inhibition of adrenal steroidogenesis by the anesthetic etomidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15764747" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Etomidate for endotracheal intubation in sepsis: acknowledging the good while accepting the bad.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3023041" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7895891" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Regulation of pituitary ACTH secretion during chronic stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3606284" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hormonal responses to graded surgical stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565501" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Steroids and the surgical patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3031124" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3036903" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Inhibition of the adrenocorticotropin response to surgery in humans: interaction between dexamethasone and fentanyl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14490937" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Spinal cord and ACTH release in adrenalectomized rats following electrical stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1269158" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of epidural analgesia on the glycoregulatory endocrine response to surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4823919" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19821345" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Supplemental perioperative steroids for surgical patients with adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/173974" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Glucocorticoid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12387243" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14252277" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : NATURAL HISTORY OF PITUITARY-ADRENAL RECOVERY FOLLOWING LONG-TERM SUPPRESSION WITH CORTICOSTEROIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4336764" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Recovery of adrenocortical function during long-term treatment with corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12594318" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Corticosteroid insufficiency in acutely ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12800537" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Perioperative management of patients treated with glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8368224" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14044395" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/645738" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Alternate-day corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5636662" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Adrenocortical responsiveness after alternate-day corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075176" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4772640" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4349334" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4349334" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14264259" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : DIURNAL VARIATION IN SUPPRESSION OF ADRENAL FUNCTION BY GLUCOCORTICOIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22127073" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Are high-dose perioperative steroids necessary in patients undergoing colorectal surgery treated with steroid therapy within the past 12 months?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12456538" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10326936" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16597078" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21932593" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids--more common than expected?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16412623" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Systemic side effects of inhaled corticosteroids in patients with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8349876" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4251769" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16384751" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Adverse effects of topical glucocorticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3553247" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24860741" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20972726" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7377855" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13549552" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Absorption of acetates of hydrocortisone, delta 1-hydrocortisone and cortisone from the joint cavity into the circulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13163092" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The use of hydrocortisone acetate (compound F acetate) in the treatment of some common orthopaedic conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19364690" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17596769" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : High risk of adrenal insufficiency after a single articular steroid injection in athletes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067555" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Epidural triamcinolone suppresses the pituitary-adrenal axis in human subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24430212" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Simultaneous bilateral knee injection of methylprednisolone acetate and the hypothalamic-pituitary adrenal axis: a single-blind case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7332377" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3311477" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970286" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19585406" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16397312" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21036888" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18438172" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Low-dose and high-dose adrenocorticotropin testing: indications and shortcomings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6281642" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
